Working… Menu

A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma (ReACT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01498328
Recruitment Status : Completed
First Posted : December 23, 2011
Last Update Posted : February 17, 2020
Information provided by (Responsible Party):
Celldex Therapeutics